Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.30 |
| ▸ | SI | P14410 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181125 | 0.81 | — | — | |
| SCHEMBL8184048 | 0.79 | STAT3 (0.31) | MGAMSI | |
| SCHEMBL7486785 | 0.79 | HTR2C (0.32) | — | |
| SCHEMBL6436811 | 0.79 | — | — | |
| SCHEMBL4953870 | 0.79 | STAT3 (0.31) | MGAMSI | |
| SCHEMBL10599330 | 0.76 | — | — | |
| SCHEMBL7407325 | 0.76 | LGALS8 (0.34) | — | |
| SCHEMBL8683152 | 0.75 | — | — | |
| SCHEMBL4953874 | 0.75 | — | — | |
| SCHEMBL271275 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-5852017-A | 2,3(1H,4H)-quinoxalinediones | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0572852-B1 | Quinoxalin-2,3(1H,4H)-diones used as medicine | BASF AG (DE) | 1998-10-21 | — | — | EP | disclosed |
| US-5714489-A | 2,3(1H,4H)quinoxalinedione | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-03 | — | — | US | disclosed |
| EP-0572852-A1 | Quinoxalin-2,3(1H,4H)-diones used as medicine | BASF Aktiengesellschaft (DE) | 1993-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | MGAM 4845/4885SI 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.